Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics (CogRx) is an innovative research and drug discovery organization focused on the development of novel therapies for neurodegenerative diseases (NDD), with a lead program in Alzheimer’s disease targeted to enter the clinic in 2014. Its Alzheimer’s disease program is comprised of small molecule therapeutic candidates that block the action of toxic soluble beta-amyloid oligomer proteins that cause progressive memory loss, the primary and devastating hallmark of Alzheimer's disease. Using its proprietary discovery platforms, CogRx has discovered first-in-class receptor antagonist compounds that selectively block these soluble beta-amyloid oligomers from causing cognitive decline. 

SUSAN CATALANO, Ph.D.
FOUNDER

  • Above:
    Old view of Alzheimer’s: Beta-amyloid fibrils and plaque are the culprit.

  • Above:
    New view of Alzheimer’s: Beta-amyloid oligomers are the culprit.

  • Above:
    Beta-amyloid oligomers binding to receptors on some of the brains cells in the dish are visible under the microscope.

  • Above:
    Oligomers are not able to bind to brain cells and block memory function in the presence of CogRx drugs.

  • Above:
    CogRx has made these groundbreaking discoveries in their South Side labs, located in a former Gimbel's warehouse, in the shadow of the old J&L steel mill.